Scleroderma Drug Development

Creative Biolabs is a leading service provider that offers drug development for autoimmune diseases. Our scientists focus on novel therapies for scleroderma and have built up several scleroderma drug development solutions for customers all over the world.

Scleroderma, or systemic sclerosis (SSc), is a chronic connective tissue disease generally classified as an autoimmune rheumatic disease. It causes sclerosis of various target organ systems: skin, kidney, lung, heart, muscles, and blood vessels. The pathogenesis of scleroderma is characterized by a constellation of humoral and cellular immunity activation, microvascular damage, and widespread tissue fibrosis. Additionally, scleroderma is classified according to skin involvement into two significant groups of limited and diffuse disease. Among them, patients with diffuse scleroderma may show visceral involvement, which is responsible for reduced life expectancy.

Treatment of Scleroderma

While the biology of the pathogenesis of scleroderma is continually better understood, scleroderma treatment is difficult and remains a great challenge to the clinician. The traditional therapeutic options include the use of (1) vasodilators (calcium channel blockers, angiotensin-converting enzyme inhibitors, and prostaglandins); (2) immunosuppressant drugs (methotrexate, cyclosporine, cyclophosphamide, and extracorporeal photopheresis); (3) antifibrotic agents (D-penicillamine, colchicine, interferon-gamma, and relaxin); and (4) phototherapy.

Fig.1 Pathogenesis of fibrosis in systemic sclerosis. (Castelino, 2014)

Progress in understanding the cellular, molecular, and biomechanical regulators of scleroderma leads to the identification of novel targets and development of new therapy options:

There is evidence that tumour necrosis factor (TNF) is an important cytokine in the early stages of scleroderma; thus, an anti-TNF antibody or anti-TNF receptor has great value for scleroderma treatment.
Disturbances in B-cell homeostasis appear to be involved in scleroderma along with abnormal activation of T cells. There is an FDA-approved monoclonal antibody against the CD20 on the surface of B cells, which can significantly improve the function and skin fibrosis with minimal adverse effects.
The anti-IL-6 receptor antibody may be of potential benefit since IL-6 appears to play a role in the pathogenesis of scleroderma.
Anti-TGF-β antibody can inhibit the action of tissue fibroblasts and improve inflammatory arthritis and disability in scleroderma.
Current systemic therapies are rarely curative for patients with severe life-threatening forms of autoimmune diseases. Although further studies are necessary, autologous hematopoietic stem cell transplantation (HSCT) seems promising in some patients with severe diffuse cutaneous scleroderma to sustain improvement of skin thickening and stabilization of organ function.

Our Scleroderma Drug Development Services

Discoveries in the pathogenesis of scleroderma herald a drastic change in the traditional out-look to therapy and have led to the development of the target-based approach and cell-based therapy. Creative Biolabs is one of the well-recognized experts who are professionals in high-quality drug development for autoimmune diseases. According to the different goals and demands, our scientists are confident in offering the best-fit drug development services for your projects based on our extensive experience and advanced platforms.

Monoclonal Antibody Development for Scleroderma
Bispecific Antibody Development for Scleroderma
Cell-based Therapy for Scleroderma

Along with our extensive experience in providing excellent services for drug development, Creative Biolabs has won an excellent reputation among our worldwide customers for accomplishing numerous challenging projects. Equipped with advanced platforms and powerful technologies, we are confident in offering the most suitable solution and achieving our customers' best outcomes. If you would like to know more about our services, please get in touch with us.

Reference

Castelino, F.V.; Varga, J. Emerging cellular and molecular targets in fibrosis: implications for scleroderma pathogenesis and targeted therapy. Current opinion in rheumatology. 2014, 26(6): 607-614.

For Research Use Only | Not For Clinical Use

Online Inquiry

Autoimmune Diseases

Contact us USA

Location:
Call:
Fax:
Email:

Location:
Call:
Email:

Germany

Location:
Call:
Email: